Condition: Generalized Pustular Psoriasis (GPP) · Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
This description comes directly from the study's public registry record.
guodong zhou · +86 13636638684 · guodong.zhou@huaota.com
Qiaoxia Qian, master · +8618555690860 · qiaoxia.qian@huaota.com
Always discuss trial participation with your own doctor first.
| Peking University People's Hospital (PKUPH) | Beijing, China | Recruiting |
| Shanghai Huaota Biopharmaceutical Co., Ltd | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06231381